A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma — Stella
A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(28 sites)
France
Institut Bergonié, Bordeaux
Centre Georges François Leclerc, Dijon
Centre Léon Bérard, Lyon
Centre Antoine Lacassagne, Nice
Institut Claudius Regaud, Toulouse
Institut Gustave Roussy, Villejuif
Germany
Helios Klinikum Bad Saarow, Bad Saarow
Charité- Universitätsmedizin Berlin, Berlin
Uniklinik Köln, Cologne
Universitätsklinikum Düsseldorf, Düsseldorf
Universitätsklinikum Frankfurt, Frankfurt
Universitätsklinik Hamburg-Eppendorf, Hamburg
Heidelberg University Hospital, Heidelberg
Universitätsmedizin der J.-G. Universität Mainz, Mainz
Klinik rechts der Isar, München
Universitaetsklinikum Muenster, Münster
Italy
IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo, Candiolo, Torino
Bologna University, Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of DIMES, Bologna
AOU San Luigi Gonzaga, Orbassano
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Poland
Szpital Pomorski Im. PCK, Gdynia
Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie Warszawa, Warsaw
Spain
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario Virgen de las Nieves, Granada
Fundación Jiménez Díaz, Madrid
Hospital General Universitario Gregorio Marañón, Madrid